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A B S T R A C T  
Glucocorticoids (GCs) are released from the hypothalan~ic-pitutitary-adrenal-axis in
response to physiological and psychological stressors. GCs initiate their signaling pathway by 
binding to Type I niineralocorticoid receptor (MR) or Type I1 GC receptor (GR) which are 
members of a large family of nuclear receptors, and have traditionally been credited with anti- 
inflammatory and in~munosuppressive actions in the periphery ~naking them a pharnlacological 
tool to treat a variety of autoimmune diseases. Recent evidence has suggested that the actions for 
GCs may be more complicated in the central nervous system (CNS). Microglia cells, the resident 
macrophage in the brain, act as a primary response component of CNS inflammatory action. To 
gain insight into the microglia response to GCs, time- and dose-dependent effects of 
dexamethasone, a synthetic corticosteroid, on microglial morphology and mRNA expression of 
GR, MR, toll-like receptor 4 (TLR4), cluster differentiation 14 (CD14), and myeloid 
differentiation factor (MyD88) were examined. The type I rnineralocorticoid receptor (MR) was 
found to be downregulated at 100 nM dose of dexametlrasone after 3 days of treatment. The 10 
nM and 1 pM concentration of dexamethasone did not elicit the same repressive effects on MR as 
the 100 nM treatments. The type I1 receptor GR and inflammatory mediators TLR4, CD14, and 
MyD88 did not show significant changes in mRNA expression following dexamethasone 
treatment. Additionally, the percentage of amoeboid cells seemed to increase after exposure to 
100 nM dexamethasone for two and three days. These data suggest that chronic exposure to 
dexamethasone may have significant effects on microglial activation and the MR mRNA 
expression without significantly affecting the mRNA expression of upstream mediators of LPS 
signaling pathway in microglial cells. 
I N T R O D U C T I O N  
Invertebrates and more complex organisms have a variety of mechanisms for responding 
to stress. In mammals, physiological changes ensue at tlie onslauglit of the stress response 
activating the hypothalamic-pituitary-adrenal (HPA) axis which ultimately results in the release 
of glucocorticoids (GCs). GCs are a group of steroid hormones that regulate a variety of 
metabolic and im~nunologic responses decreasing accessory activities such as digestion and 
growth i n  reaction to stress. The endogenous GC corticosterone is involved in basal activities 
maintaining the coordination of circadian events like the sleeplwake cycle, food intake, and 
permissive regulation of the organisms' sensitivity to stress (De Kloet et al., 1998). In tlie central 
nervous system (CNS), the GCs at basal levels have been shown to increase synaptic plasticity, 
decrease neuronal cell death, and facilitate certain levels of hippocampus-dependent cognition 
(McEwan and Magarinos, 200 1 ). 
GCs have demonstrated anti-inflammatory action in the periphery reducing expression of 
pro-inflammatory cytokines including IL- I P, IL-6, and TNF-u and enhancing anti-inflammatory 
molecules including IL-10 and TGF-P (Correale et al., 1998; Gayo et al., 1998). GCs' anti- 
inflammatory properties have been utilized pharmacologically to tnodulate inflamniatio~i in 
instances of allergies, asthma, and autoimmune disease, and as a post-operative measure to 
alleviate neuroinflammation (Hockey et a]., 2009). While the clinical doses of GC are 
administered as anti-inflammatory agents, the complexity, duration, and severity of the 
physiological stress response present a more challenging picture of GC mediated actions in the 
brain. The immune response in tlie CNS is distinct from other tissues due to the blood brain 
barrier (BBB) which allows for a specialized microenvironment that is largely separate from that 
of the systemic organs (Risau and Wolberg, 1990). The lack of professional antigen presenting 
cells, and the limited expression of major histocompatibility conlplex, along with the presence of 
the BBB create an immunologically privileged environment in the CNS (Wekerle et al.. 1986). 
Recent investigations of glucocorticoid response in the CNS present an array of studies 
that challenge and support the classical view of GCs' anti-inflammatory action. At the cellular 
level, dexamethasone. a synthetic corticosteroid, has been shown to reduce oxidative damage 
associated with inflammation (Golde et al. 2003). In contrast, rats exposed to chronic stress 
through restraint show an increase in microglia density and activation in multiple brain regions 
(Tynan et al., 20 10). Low concentrations of corticosterone inhibit the expression of 
proinflammatory cytokines 11- 1 p and TNF-a at the mRNA level in the rat hippocampus 
following an excitotoxin kainic acid stimulus (MacPherson et al., 2005), while high levels of 
corticosterone in rats exposed to unpredictable stress increase the levels of LPS-induced 
inflammatory signaling mediator NF-KB in the hippocampus (Munhoz et al., 2006). Evidence for 
a proinflammatory GC response is also indicated by the ability of endogenous GC to induce 
synthesis of macrophage migration inhibitory factor (MIF) in the mouse CNS. MIF is credited 
with a wide range of proinflammatory action including induction of TNF-a synthesis in 
macrophages, iNOS activib in microglia, and T-cell activation (Dinkel et. al. 2002; Donnelly and 
Bucala, 1997; Leech et. al. 1999) 
GCs signaling pathway utilizes Type I mineralocorticoid receptor (MR) and Type I1 GC 
receptor (GR) which are members of a large family of nuclear receptors. These receptors consist 
of three major functional domains: an N-terminal domain, a central DNA binding domain, and a 
hinge region that links N-terminal domain and DNA binding domain to a C-terminal ligand 
binding domain. The N-terminal domain of MR is the longest of all the steroid receptors which 
are subjected to a high degree of variability with less than 15% identity within the steroid receptor 
family. Even so each individual receptor is highly conserved with over 50% homology observed 
among various vertebrate species, which suggests an important fi~nctional role for the steroid 
receptor family (Viengchareun et al., 2007). When unoccupied, the receptors are attached to heat 
shock proteins including hsp90 and hsp70 which fimction in maintaining receptor conformation 
to facilitate ligand binding. Upon ligand binding, the receptors shed their protein chaperones, 
homodimerize, and translocate into the nucleus where it can exert either direct or indirect 
regulation of the expression of their target genes (Sorrells and Sapolsky, 2006). The receptors 
could directly influences the transcription of its target genes through its binding to GC response 
elements (GRE) located in the promoter regions. When core GR binding domains are not directly 
available, GR may link to promoters through binding with other transcription factors so that GR 
is associated by protein-protein interactions rather than direct DNA binding (Lefstin and 
Yamamoto, 1998). Chromatin in~munoprecipitation experiments have demonstrated that 
occupancy of GR binding sites can be influenced by post-translational modifications (Blind and 
Garabedian, 2008). It has also been reported that GR is subjected to post-translational 
modification through phosphorylation at serinelthreonine residues located in DNA binding 
domains, which induces conformational changes and provides a possible mechanism for GR 
mediated transactivation (Webster et al., 1997). Ft~l-thermore. GR stability is sensitive to its 
phosphorylation status which can affect the half-life and ligand-dependent stabilization 
suggesting a critical role of post-translational modification in receptor turnover (Hittelman et al., 
1999; Liberman at al., 2007). 
In the hippocampus, MR has been shown to exhibit increased binding with a ten fold 
higher affinity for endogenous GC than GR (De Kloet et al., 1998). While MR and GR share 
significant honlology in their DNA binding domains they do not exclusively target the same set 
of genes. In the rat hippocampus, activation by the respective receptors shows less than a 30% 
overlap of their target genes, demonstrating the potential for a receptor specific cellular response 
(Datson et al. 2001). MRs' high binding affinity for GCs (Kd = 0.5nM) suggests that at basal 
levels MR is the more highly occupied receptor with only slight saturation of GR (Kd = 5.0nM) 
(De Kloet et a]., 1998). Early i~ivestigations into glucocorticoid receptor binding showed that rats 
sacrificed early in the morning at the nadir ofthe HPA axis diurnal rhythm exhibited hipocampal 
MRs that were 80% occupied while G R  was only 10% occupied. GR binding increased only 
when a higher level of corticosterone was introduced as is the case during stress (Reul and De 
Kloet, 1985; Reul et al., 1987). Differential binding by the two receptors in brain cells may play 
a role in the varied effects of GCs observed in the CNS (Sapolsky et al., 2000). In vitro binding 
studies indicate that naturally produced steroid hormones such as corticosterone and cortisol 
preferentially bind to MR as compared to synthetic GCs like dexamethasone which show higher 
affinity for GR (Rupprecht et al 1993). These receptors have been identified in cell types that are 
essential to the inflamniato~y response including dendritic cells, macrophages, lymphocytes, and 
microglia cells (Fuxe et al., 1985; Sierra et al., 2008). 
Microglia cells play a critical role in the innate immune response in the brain. The innate 
immune system is an inherent defense system that offers an immediate response to an immune 
challenge. Microglia are the resident macrophages of the nervous system and fu~iction as antigen 
presenting cells and phagocytic scavengers that are continuously sampling the surrounding 
environment for even the smallest disruption, and can be activated by a variety factors such as 
infection, physical trauma, oxygen depletion, and neurodegeneration. The number of microglia 
cells present increases in response to a variety of CNS insults such as restraint induced chronic 
stress in mice ( Tynan et al., 20 10). Immunohistochemical detection indicates that the microglia 
cells are the first population to respond with a proliferative response to a CNS stressor such as 
infection or physical trauma (Postler et al., 1997; Hailer, 2008). When neuronal cell death occurs, 
glutamate, prostaglandins, cytokines, and other cellular contents are released into the surrounding 
area resulting in activation of microglia and migraticn to the damaged site. The activated 
microglia work to restore homeostasis and are characterized by proliferation and a morphological 
change from the ramified resting state to the motile amoeboid morphology that is accompanied by 
an increase in production of pro-inflammatory cytokines such as IL-6, IL-18, and TNF-a 
(Sugama et al., 2007). Chemokines and co-stimulatory molecules CD40 and CD8O are also 
produced in the activated microglia, which are necessary for T-cell activation (Dimayuga et al, 
2005). 
Microglial reaction to an invading pathogen depends on toll-like receptors (TLR) that 
are expressed on the microglia cell surface and these TLRs act as pattern recognition receptors for 
pathogen-associated molecular patterns (PAMPs). LPS from gram-negative bacteria cell wall is 
one of such PAMPs. It is bound by TLR4 and its co-receptor CD 14. The activation of TLR4 
initiates recruitment of myeloid differentiation factor 88 (MyD88). MyD88 is a cytosolic adapter 
protein that is a key component of the signal transduction pathways for interlukin-l and toll-like 
receptor. These pathways regulate extensive proinflammatory responses. The MyD88 protein 
consists of an N-terminal death domain and a C-terminal Toll-interlukin 1 receptor domain (Han, 
2006). Following TLR4 binding, MyD88 associates with IL-l receptor associated 
Kinase (IRAK) complex through its amino terminal death domain, which ultimately results in the 
activation of NF-KB. NF-KB is a crucial activator of genes encoding innate immune proteins such 
as cytokines, chemokines, complement proteins, and cell adhesion molecules (Beutler, 2000; 
Glezer et al., 2007). 
Recognition of a foreign ligand, such as bacterial LPS, initiates microglia activation and 
the pro-inflammatory signaling cascade (Poltorak et al., 1998). The rapid up-regulation of 
proinflammatory products aids in defense against the immune challenge but also potentially 
contributes to neurological damage under conditions of chronic inflammation. For example, 
activated microglia has been indicated as a contributing factor in neurodegeneration resulting 
from the production of oxygen and nitrogen reactive species and prolonged exposure to 
inflammatory cytokines (Glezer et al., 2007). 
GCs are well-known to be released as a feedback mechanism to quench an inflammatory 
response, however, more recently they have been shown to have proinflammatory effects. 
Furthermore, the effects of chronic exposure to GCs in the brain have been suggested to be more 
complex than its acute anti-inflammatory effects in the periphery. The purpose of this study is to 
investigate the effects of GCs on the basal expression of innate immune mediators in microglial 
cells when they are not exposed to any inflammatory challenges. Microglia cells were grown in 
vitro and treated with the synthetic corticosterone analogue dexamathesone at 10 nM, 100 nM, 
and 1 pM concentrations. Three days following dexamethasone exposure, cells were collected and 
processed to examine the relative mRNA levels of steroid receptors MR and GR, as well as the 
upstream components of the inflammatory response such as TLR4, CD14, and MyD88. A time 
course of 100 nM dexamethasone treatment was done in order to evaluate the response of 
microglia cell to the duration of GC exposure. RNA was isolated from the treated populations 
after 1,2, and 3 days of exposure and the expression of the steroid receptors and inflammatory 
mediators were determined using RT-PCR analysis. 
M A T E R I A L S  A N D  M E T H O D S  
Cell Culture 
BV2 is a murine microglial cell line kindly provided by Dr. Jau-Shyong Hong from 
National Institute of Health. These cells were grown in Dulbecco's Modified Eagle's Medium 
(DMEM) containing 10 % Fetal Calf Serum (FCS) and 1 %  penlstrep antibiotic. Cells were 
cultured in T-75 cm2 flasks (Corning, Corning NY) at 37OC in a humidified incubator with 5% 
C02. Once microglia were grown to confluence the cells were washed with PBS and detached 
from the flask using trypsin. The cells were counted on a hemocytonieter and plated for treatment 
as described below. 
Dexamethasone Treatments 
BV2 cells were counted using a hemocytometer and then seeded into 6 well plates. For 
dose response experiments, I .O x 10'cells per well were used for a 6 well plate. One day after 
seeding, cells were treated with 10 nM, 100 nM, or 1 pM of dexamathasone (Sigma-Aldrich, St. 
Louis MO) for 3 days with the control cells left untreated. For time course experiments, 2.0 x 
lo5, 1.5 x 1 05, and 1.0 x 10' cells were seeded and treated with 100 nm dexamethasone the 
following day for 1,2, and 3 days respectively. 
RNA Extraction 
Total RNA was isolated from the cell culture plates using Trizol reagent (MRC, 
Cincinnati, OH ). The media was aspirated from each well, then 500 pJ of Trizol was added to 
lyse the cells. The suspension was transferred to 1.5 ml centrifuge tubes followed by 100 p.1 of 
chloroform. Samples were centrifuged at 4OC for 15 nlinutes at a speed of 12,000g. The upper 
aqueous phase was transferred to a new tube and 250 pI isopropanol was added to precipitate 
RNA. The sample was spun at 12,000g for 8 minutes to form a pellet. The pellet was washed in 
75% ethanol and resuspended in RNase free HzO. RNA concentrations were determined using a 
spectrophotometer. 
Reverse Transcriptase- Polymerase Chain Reaction (R T- PCR) 
Reverse transcription reactions were set LIP using 2 pg of total RNA, oligo (dT)12.18 
primer, and Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (Invitrogen, Grand 
Island, NY). Following cDNA synthesis, PCR amplification reactions were carried out in 0.2 nil 
PCR tubes with Ix PCR buffer, 0.2 niM dNTPs, I unit Taq DNA polynlerase, 0.5/~1 of each sense 
and antisense primer, and 1/11 cDNA for a total reaction volume of 20pl. Primers for mouse P- 
actin, myd88, MR, CD14, GR, TLR4 were run with an annealing temperature of 56•‹C for P- 
actin, and 57" C for the remainder of the primers. B-actin was run for 21 cycles using primers 5'- 
AGC-CAT-GTA-CGT-AGC-CAT-CC-3' and 5'-CTC-TCA-GCT-GTG-GTG-GTG-AA-3'. 
Myd88 was run for 27 cycles with primers 5'-TGT-CCC-AAA-GGA-AAC-ACA-CA-3' and 
5'ACT-GGC-CTG-AGC-AAC-TAG-GA-3'. MR was run for 30 cycles with primers 5'-GCA- 
AAA-TCC-CAG-ACC-GAC-TA-3' and 5'-CAG-ACC-TTG-GAG-CGT-TCT-TC-3'. CD 14 was 
run for 25 cycles with primers 5'- CTG-ATC-TCA-GCC-CTC-TGT-CC-3' and 5'-GCT-TCA- 
GCC-CAG-TGA-AAG-AC-3'. GR was run for 25 cycles with primers 5'-CCA-CTG-CAG- 
GAG-TCT-CAC-AA-3' and 5'-AAG-GGT-CAT-TTG-GTC-ATC-CA-3'. TLR4 was run for 28 
cycles with primers 5'- GGC-AGC-AGG-TGG-AAT-TGT-AT-3 ' and 5'- CTT-AGC-AGC-CAT- 
GTG-TTC-CA-3'. Following the PCR reactions, amplified DNA samples were separated on a 
2.0% agarose gel. The gels were visualized and documented using the UVP ~ e l ~ o c ~ t ~ "  imaging 
system (UVP, Upland CA). The intensities of the respective bands were analyzed by digital 
densitometry using Vision works' LS software (UVP, Upland CA). 
Data Analysis 
The band intensity of the RT-PCR data was normalized to p-actin. All data were 
presented as the mean * SEM for each control or treatment group. Statistical comparisons were 
performed using one-way ANOVA with repeated measures for the dose response experiments 
and a two-way ANOVA with repeated measures for time course experiments using factors of 
time and treatment (treated vs. untreated). 
Phase Contrast Microscopy 
Images of the microglia cells were obtained using an inverted phase contrast Leica DMIL 
microscope with a Leica DFC 300 CCD camera. Images were collected during each day of the 
dexamethasone treatment. Cells were quantified manually by counting the ramified, ameboid, 
and total cell number present on each day of treatment. Ramified cells were defined as those with 
oval to oblong shaped soma that have thin projections (Glenn et al., 1992). Ameboid microglial 
cells were identified by their enlarged cell bodies with a granular appearance and short stubby 
projections or lack of projections (Rock et al., 2004). 
RESULTS 
Phase contrast imaging of microglia cells after treatment with different doses of dexamethasone 
Phase contrast microscopy was used to examine morphology of microglia treatment 
groups. Ramified microglia cells are the resting stage of the microglia that is composed of 
projecting branching attached to an elongated cylindrical cell body. The amoeboid form of a 
microglia cell is phagolytically active exhibiting an enlarged rounded cell body with lysosomes 
and possible pseudopodia like processes (Becher and Antel, 1996). The microglial cells cultured 
in vitroexhibited both populations of ramified and ameboid cells (Fig. I). In the untreated cells 
after three days, 9 % of the cells appeared ramified while 4% exhibited the ameboid phenotype. 
After treatment with 10 nM dose of dexamethasone for three days, 14 % of the total cell 
population exhibited ramified phenotype while 9 % of the total cell population had visible 
ameboid morphophology. After treatment with 100 nM dose of dexamethasone for three days, 
there were about 9% of cells exhibiting ramified phenotype and 12 % of the cell population 
exhibiting ameboid morphology. After treatment with 1 pM dexarnethasone for three days, there 
were about 19 % of the microglia population exhibiting ramified phenotype and 12% of the cells 
exhibiting ameboid characteristics (Fig 1 and Fig. 2). Even though more repeats are needed to 
perform statistica1 analysis, it seemed that dexamethasone treatment may have an effect on the 
morphology of microglial cells in culture. 
Figure I .  Representative images of microglia after three days of treatment with different 
concentrations of dexamethasone in culture. (a) Untreated microglia. (b) Microglia treated with 
I0 nM dexamethasone. Mote the appearance of ramified cells (black arrow). (c) Microglia treated 
with 100 nM dexamethasone with ameboid cells present (white arrow). (d) Microglia treated with 
1 pM dexamethasone with increased numbers of ramified cells observed (black arrow). Scale bar 
represented 50 pm. 
Microglia Cell Phenotype 
Control 10 nM 100 nM 1 CIM 
Treatment 
Figure 2. Percentage of ramified (blue diamond) and ameboid (red square) microglia cells after 
treatment with 10 nM, 100 nM, and 1 pM dexamethasone for 3 days. 
Dexamathasone induced dose-dependent dowr~regulation of Type I mineralocorticoid receptor in 
microglia 
To examine the effects of glucocorticoid exposure on microglia expression of inflammatory 
mediators, microglia cells were grown in vitr0 and treated with 10 nM, 100 nM, or 1 pM of 
dexamethasone. After three days of dexamethasooe treatment, the cells were collected and 
processed for total RNA extraction. RT-PCR analysis was used to determine the expression 
levels of the primary type I and type I1 GC receptors MR and GR. 
Analysis of mRNA expression shows that MR was decreased at 100 nm treatment 
compared to the untreated control. MR expression was unaffected at a I0 nM concentration of 
dexamethasone. When the concentration of the corticosteroid was increased from 100 nM to 1 
pM, the expression of MR returns to a level similar to that of the untreated control resulting i n  a 
U-shaped dose dependent expression pattern after three days of exposure to different 
dexamethasone concentrations (Fig. 3). 
The mRNA expression of GR following exposure to different concentrations of 
dexamethasone was also examined. Even though the GR mRNA expression appeared to be 
slightly up-regulated after treatment with 10 nM, 100 nM, and 1 pM dexamethasone as compared 
to control cells, but the increase was not significant (Fig. 4). 
Control lOnM lOOnM IpM 
M 
MR Dose Response 
Control 10nM 100nM l u m  
Treatment 
Figure 3 .  (A) Representative agarose gel image of MR expression in microglia cells at 3 days 
following treatment with 10 nM, 100 nM or 1 pM of dexamethasone using semi-quantitative RT- 
PCR. (B) Quantitation of MR mRNA expression normalized to P-Actin. Statistical analysis was 
done by one way ANOVA, and values were means S E .  (*P < 0.05). 
Control lOnM IOOnM lvM 
A A A  
GR Dose Response 
Control 10nM 100n M l u m  
Treatment 
Figure 4. (A) Representative agarose gel image of GR expression in microglia cells at 3 days 
following treatment with 10 nM, 100 nM or 1 pM of dexamethasone using semi-quantitative RT- 
PCR. (B) Quantitation of GR mRNA expression normalized to P-Actin. Statistical analysis was 
done by one way ANOVA, and values were means +SE. 
Dexamethasone had no dose dependent effects on the mRNA expression of upstream mediators of 
1 PS signaling path way 
To examine the effects of glucocorticoid exposure on microglia expression of inflammatory 
mediators, microglia cells were grown in vitroand treated with I0 nM, 100 nM, or 1 pM of 
dexamethasone. Microglia cells were exposed to the dexamethasone treatment for three days and 
then harvested for total RNA extraction. The relative mRNA expression levels of upstream 
mediators of LPS signaling pathway such as TLR4, CD14, and MyD88 were determined using 
RT-PCR analysis. 
The TLR4 mRNA level i n  cells treated with I0 nM and 
to that in control cells (Fig. 5).  TLR4 mRNA in cells treated wil 
I pM dexamethasone was similar 
th I00 nM dexamethasone 
appeared to be lower than that in control cells, but the difference was not statistically significant 
(Fig. 5). 
The mRNA expression of CD 14 following treatment with I0 nM and 1 OOnM 
dexamethasone did not valy significantly from that in untreated microglia cells. The co-receptor 
CDI 4 appeared to be upregulated at the I pM dose of dexamethasone but the change was not 
statistically significant (Fig. 6). The mRNA expression of Myd88 did not appear to be 
significantly affected by treatment with I0 nM, 100 nM, or I pM of dexarnethasone for three 
days (Fig. 7). 
TLR4 Dose Response 
m 
- 
a Control 10nM 100n M lum 
Treatment 
Figure 5. (A) Representative gel image of TLR4 expression in microglia cells at 3 days following 
treatment with 10 nM, 100 nM or 1 pM of dexamethasone using semi-quantitative RT-PCR. (B) 
Quantitation of TLR4 mRNA expression normalized to a-Actin. Statistical analysis was done by 
one way ANOVA, and values were means *SE. 
Control lOnM lOOnM luM 
Control 10nM 100nM 
Treatment 
Figure 6. (A) Representative gel image of CD14 expression in microglia cells at 3 days following 
treatment with 10 nM, 100 nM or 1 pM of dexamethasone using semi-quantitative RT-PCR. (B) 
Quantitation of CD14 mRNA expression normalized to P-Actin. Statistical analysis was done by 
one way ANOVA, and values were means *SE. 
Control lOnM 100nM ivM 
MydB8 Dose Response 
Control 10nM 100nM 
Treatment 
l um 
Figure 7. (A) Representative gel image of Myd88 expression in microglia cells at 3 days 
following treatment with 10 nM, 100 nM or 1 pM of dexamethasone using semi-quantitative RT- 
PCR. (B) Quantitation of Myd88 mRNA expression normalized to P-Actin. Statistical analysis 
was done by one way ANOVA, and values were means *SE. 
Phase contrast images of microglia cells during time course dexamethasone treatment 
Phase contrast images were taken of the microglia cells after 1,2, and 3 days of 100 nM 
dexamethasone treatment. The 100 nM treatment was chosen considering that at this 
concentration, dexamethasone significantly affected the mRNA expression of MR following three 
days of treatment. After the first day of time course, 3 % of the untreated cells exhibited ramified 
morphology and 4 % appeared ameboid while the cells treated with 100 nM of dexamethasone 
contained 5 % ramified and 4 % ameboid phenotypes in the total cell population. After second 
day of dexamethansone treatment, 9 % of the untreated microglia were ramified cells, while less 
than 1 % of the population appeared ameboid. The amount of ramified and ameboid cells 
appeared to increase on day two in treated microglia as compared to the untreated cells, with 13 
% of the treated cells identified with ramified morphology and 4 % exhibiting the ameboid 
phenotype. On the third day of treatment 11% of the untreated cells appcared ramified while 2 % 
showed amoeboid morphology. After three days of 100 nM dexamethasone treatment 10 % of 
the cells were ramified and 4% of the population appeared ameboid (Fig. 8 and Fig. 9). 
Figure 8. Representative iniages of nlicroglia in culture following 100 nM treatment 
dexamethasone for different days. (a) Untreated microglia after 1 day. (b) Microglia treated with 
100 nni for 1 day. (c) Untreated microglia after 2 days. (d) Microglia treated with 100 nM for 2 
days. (e) Untreated niicroglia after 3 days. ( f )  Microglia treated with 100 niM dexaniethasone for 
3 days. Scale bar represents 50 pM. Ramified cells indicated by black arrows, ameboid cells seen 
by white arrows. 
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Figure 9. (A) The percentage of observed ramified cells in the untreated (blue diamond) and cells 
treated with 100 nM dexamethasone (red square) for 1,2, and 3 days. (B) The percentage of 
ameboid microglia cells in the untreated (blue diamond) and treated (red square) cell populations 
after 1; 2, and 3 days. 
Time dependent effects of dexamethasone on the expression of MR in microglial cells 
Microglia cells were treated with 100nm dexamethasone for 1,2, and 3 days to assess the 
effect of different durations of treatment on mRNA levels of the glucocorticoid receptors. 
MR was expressed at low levels in both the control and the treatment cell populations on 
day 1 of dexamethasone exposure. The expression level of MR slightly increased in both the 
control and treated sets of cells by day 2 of treatment. After three days of treatment with 
dexamethasone, the mRNA expression of MR significantly decreased in the treated cell 
population as previously observed in the dose response (Fig. 10). 
The GR receptor expression was consistent throughout the three days of treatment. The 
100 nM concentration of dexamethasone used and the duration of treatment from day 1 to day 3 
appear to have little effect of the expression of GR in the microglia cell (Fig. 1 1). 
Control Dav 1 Control Dav 2 Control Dav 3 
MR Time Course 
-- 
Treated 
Day 1 Day 2 Day 3 
Duration of Treatment 
Figure 10. Representative gel image of MR RT-PCR following treatment with 100nM 
dexamethasone for 1 ,2 ,  or 3 days. (B) Quantitation of MR expression normalized to P-Actin. 
Statistical analysis was done by two way ANOVA, and values were means *SE. (*P< 0.05) 
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Figure 1 1. Representative gel image of GR RT-PCR following treatment with 1 OOnM 
dexamethasone for 1,2, or 3 days. (B) Quantitation of GR expression normalized to P-Actin. 
Statistical analysis was done by two way ANOVA, and values were means *SE. 
Dexamethasone had no effects on the expression of upstream L PS signaling mediators in 
microglial cells 
The mRNA expression of TLR4 appeared to be slightly increased after one day of 
dexamethasone treatment and decreased thereafter as the duration of treatment increased to two 
and three days, yet these changes were not statistically significant. Therefore, TLR4 mRNA 
expression did not appear to be significantly affected by the 100 nm treatment (Fig. 12). 
No changes in the mRNA expression of CD14 co-receptor and the signal mediator 
Myd88 were observed after the first day of the treatment with dexamethasone. The expression of 
CD 14 and MyD88 increased slightly on the second day of treatment, and then returned to basal 
level of expression thereafter, but these changes were not statistically significant. Therefore, the 
rnRNA expression of inflammatory mediators CD14 and myD88 appeared to be largely 
unaffected by the exposure to I00 nM dexamethasone (Fig. 13 and Fig. 14). 
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Figure 12. Representative gel image of TLR4 RT-PCR following treatment with I OOnM 
dexamethasone for 1,2, or 3 days. (B) Quantitation of TLR4 expression normalized to P-Actin. 
Statistical analysis was done by two way ANOVA, and values were means *SE. 
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Figure 13. Representative gel image of CD14 RT-PCR following treatment with 1 OOnM 
dexamethasone for 1,2, or 3 days. (B) Quantitation of CD14 expression normalized to 0-Actin. 
Statistical analysis was done by two way ANOVA, and values were means S E .  
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Figure 14. Representative gel image of Myd88 RT-PCR following treatment with 1 OOnM 
dexamethasone for 1,2, or 3 days. (B) Quantitation of Myd88 expression normalized to P-Actin. 
Statistical analysis was done by two way ANOVA, and values were means *SE. 
DlSCUSSl  O N  
The current study investigated the effects of dexamethasone treatment on microglial 
function using BV2 microglia cell line as an in vitro model. GCs have traditionally been credited 
with anti-inflammatory action which is why they are so commonly used in clinical settings. 
Recently growing evidence has demonstrated possible pro-inflammatory effects for GCs in the 
CNS. In this study the treatment of microglia cells with 100 pM dexamethasone appeared to 
increase the percentage of ameboid cell population after two and three days of  treatment as 
compared to controls. While components of the innate immune response, namely TLR4, mydS8, 
and CD14, showed little variation in mRNA expression after treatment with 10 nM, 100 nM and 
1 yM dexamethasone, the mRNA expression of MR significantly decreased in microglial cells 
after treatment with 100 nM of dexamethasone for three days. 
In the dose response experiment, the number of observed amoeboid cells after treatment 
with 100 nM and 1 pM dexamethasone for three days appeared to be higher than that after 
treatment with 10 nM dexamethasone and controls, suggesting that the 100 nM and 1 y M  
dexamethasone treatment may increase activation of the microglia cells even though these 
experiments remained to be repeated. Furthermore, it would be advantageous to identify 
microglia activation markers such as ionized calcium-binding adaptor molecule-l (Jba-I) and 
major histocompatibility complex I1 (MHC-11) in the treated cell population to molecularly 
differentiate the resting cell from the activated cells in populations exposed to GCs (Tynan et al. 
20 10). 
Dexamethasone exposure for three days at 100 nM showed a significant decrease in the 
expression of the type I mineralocorticoid receptor (MR). Treatment with increasing 
conce~itratio~is of dexamethasone produced a U-shaped curve of effects on MR expression. 
Dexamethasone did not have effects on MR expression at IOnM, significantly inhibited the gene 
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